Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
Go back to Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial| (NASDAQ: BBIO) | Delayed: 66.58 -0.03 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.61 | 52 Week High | $ | |||
| Open | $67.01 | 52 Week Low | $ | |||
| Day High | $67.33 | P/E | N/A | |||
| Day Low | $65.78 | EPS | $ | |||
| Volume | 3,155,884 | |||||
